Corticosteroid Responsiveness Following COPD Exacerbations with Respiratory Failure
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Study Question
COPD exacerbations with respiratory failure have an outsized impact on morbidity, mortality, and healthcare costs. Physicians treat these severe events with high doses of corticosteroids out of concern for intrinsic corticosteroid resistance. This study was designed to determine whether people who suffer from exacerbations with respiratory failure have intrinsic steroid resistance that could affect that decision.
Patients and Methods
A matched, case-control study was performed at University of Colorado. Subjects were enrolled into the Exacerbation group if they were hospitalized for an exacerbation requiring ventilation, or into the Stable COPD group if they had no inpatient exacerbation within 12 months. Stable COPD subjects were frequency-matched to Exacerbation subjects for age, smoking status and FEV 1 %. Corticosteroid sensitivity was assessed ex vivo and in vivo >45 days following the last exacerbation during a period of relative quiescence. The primary outcome was the group difference in methylprednisolone IC 50 for LPS-stimulated IL-8 release by mononuclear cells.
Measurements and Main Results
The Exacerbation group (N=8) had more exacerbations in the prior year (6.0 vs. 0.5; p<0.01) and had higher baseline blood lymphocytes (p<0.01) versus Stable controls (N=8). Ex vivo , methylprednisolone equally suppressed IL-8, IL-6, TNFa and IL-1β release by mononuclear cells and whole blood across groups. In vivo , methylprednisolone decreased plasma mediators and mononuclear cells in both groups but had a small differential effect on mononuclear cell gene expression. Answer to the Question . Exacerbations with respiratory failure have persistent lymphocytosis, an altered gene response to corticosteroids, but no corticosteroid resistance to suppress inflammation.
